A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination With Atezolizumab Compared With Atezolizumab Alone in Subjects With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 10 Sep 2018
At a glance
- Drugs Atezolizumab (Primary) ; Daratumumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CALLISTO; DARZALEX
- Sponsors Janssen Research & Development
- 05 Sep 2018 Trial has been completed in Poland.
- 17 Aug 2018 Planned End Date changed from 14 Oct 2019 to 22 Apr 2019.
- 26 May 2018 Status changed from recruiting to discontinued, as reported in the Genmab media release.